lu177

PRRT is finally approved in the U.S.

After years of randomized trials and nearly two decades of European data detailing peptide receptor radionuclide therapy, Advanced Accelerator Applications (AAA), a Novartis company, is pleased to announced that the FDA has approved the use of this therapy for patients with neuroendocrine tumors. The approval comes at a time when incidence of neuroendocrine cancers of the pancreas, lungs, and intestines are on the rise. About 7 in 100,000 people are

Dr. Thor & Dr. Tuba present The Future of PRRT & The Team Approach

On January 14, 2018, Dr. Thor Halfdanarson and Dr. A. Tuba Kendi from Mayo Clinic Rochester presented to Northwoods NETS. Dr. Tuba, a radiologist from Mayo, has been fronting the Gallium-68 PET/MRI scan center that has been helping detect and diagnose neuroendocrine tumor patients. She is now at the forefront the PRRT (peptide receptor radionuclide therapy) at the Rochester clinic. Dr. Thor presented his vision for the newly designated Neuroendocrine

FDA: Lutathera Action Date Set for Late January 2018

Advanced Accelerator Applications S.A. (AAA) has announced that the Food and Drug Administration (FDA), in the United States, has accepted and considered complete the resubmission of the New Drug Application (NDA) for its investigational drug lutetium Lu 177 dotatate (Lutathera).  Lutathera is the brand name for the radiologic used in Peptide Receptor Radionuclide Therapy (PRRT). The FDA has set an action date of Jan 26, 2018. AAA is attempting to obtain U.S.

Expanded Access to PRRT in the United States

We have exciting news in regards to Peptide Receptor Radionuclide Therapy (PRRT) therapy in the United States. Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). Considering that Phase III NETTER-1 clinical trial recruitment has been completed, this expanded access therapeutic protocol aims to allow patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy to access the investigational product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to

Part Nine: Round Two Wrap Up | PRRT & Me

  It’s been a slow, sleepy summer… I’m eight weeks out from round two and happy to report, I am doing well. I won’t lie and say that it’s been all wine and roses the last few weeks. (Mmmm, wine and roses…) I have been *so* tired. The hammer came down during week two and my exhaustion really peaked at week four. It finally started leveling out about week six. I